Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Fractyl Health, Inc. ( (GUTS) ) has issued an update.
On December 30, 2025, Fractyl Health’s board appointed Lara Smith Weber as Chief Financial Officer, effective January 12, 2026, succeeding Lisa Davidson, who resigned as CFO effective December 31, 2025, after a decade with the company; Fractyl emphasized that her departure was amicable and not due to any disagreement with management. Smith Weber, a veteran finance executive with experience at Inari, ONWARD Medical and MorphoSys in guiding growth-stage medtech and biotech firms into commercial operations, will become Fractyl’s principal financial and accounting officer and receive a compensation package including salary, bonus eligibility, a sizable four-year vesting stock option grant, and change-in-control severance protections, while Davidson will receive a year of salary, bonus, extended COBRA coverage, accelerated vesting of time-based equity, and a three‑month consulting engagement to support a smooth transition as the company prepares for its next phase of commercial-scale growth in metabolic therapeutics.
The most recent analyst rating on (GUTS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Fractyl Health, Inc. stock, see the GUTS Stock Forecast page.
Spark’s Take on GUTS Stock
According to Spark, TipRanks’ AI Analyst, GUTS is a Neutral.
The score is held back primarily by very weak financial performance (large losses, heavy cash burn, and negative equity), partially offset by constructive technical momentum and a relatively positive earnings-call outlook on clinical milestones and funding runway. Valuation contributes modestly negatively due to the negative P/E and lack of dividend support.
To see Spark’s full report on GUTS stock, click here.
More about Fractyl Health, Inc.
Fractyl Health, Inc., based in Burlington, Mass., is a metabolic therapeutics company developing “pattern‑breaking” approaches that target the organ-level root causes of obesity and type 2 diabetes to move treatment from chronic symptom management toward durable, disease-modifying therapies. The company holds a sizable intellectual property portfolio, with 35 granted U.S. patents and roughly 45 pending U.S. applications, alongside numerous foreign patents and applications, underscoring its focus on innovation in metabolic disease.
Average Trading Volume: 2,877,614
Technical Sentiment Signal: Buy
Current Market Cap: $282.3M
See more data about GUTS stock on TipRanks’ Stock Analysis page.